4NCG

Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.217 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Cote, B.Burch, J.D.Asante-Appiah, E.Bayly, C.Bedard, L.Blouin, M.Campeau, L.C.Cauchon, E.Chan, M.Chefson, A.Coulombe, N.Cromlish, W.Debnath, S.Deschenes, D.Dupont-Gaudet, K.Falgueyret, J.P.Forget, R.Gagne, S.Gauvreau, D.Girardin, M.Guiral, S.Langlois, E.Li, C.S.Nguyen, N.Papp, R.Plamondon, S.Roy, A.Roy, S.Seliniotakis, R.St-Onge, M.Ouellet, S.Tawa, P.Truchon, J.F.Vacca, J.Wrona, M.Yan, Y.Ducharme, Y.

(2014) Bioorg.Med.Chem.Lett. 24: 917-922

  • DOI: 10.1016/j.bmcl.2013.12.070

  • PubMed Abstract: 
  • The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically rele ...

    The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically relevant, resistant mutant HIV viruses. The overall favorable preclinical pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human. NNRTI 36, now known as MK-1439, is currently in clinical development for the treatment of HIV infection.


    Organizational Affiliation

    Merck Frosst Centre for Therapeutic Research, 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1, Canada. Electronic address: bernard.cote67@videotron.ca.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Reverse transcriptase/ribonuclease H
A
563Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)Mutation(s): 0 
Gene Names: gag-pol
Find proteins for P04585 (Human immunodeficiency virus type 1 group M subtype B (isolate HXB2))
Go to UniProtKB:  P04585
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
p51 RT
B
443Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)Mutation(s): 2 
Gene Names: gag-pol
Find proteins for P04585 (Human immunodeficiency virus type 1 group M subtype B (isolate HXB2))
Go to UniProtKB:  P04585
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
2KW
Query on 2KW

Download SDF File 
Download CCD File 
A
3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile
C17 H11 Cl F3 N5 O3
ZIAOVIPSKUPPQW-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.217 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 118.385α = 90.00
b = 153.618β = 90.00
c = 154.624γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data reduction
ADSCdata collection
HKL-2000data scaling
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2013-10-24 
  • Released Date: 2014-02-12 
  • Deposition Author(s): Yan, Y.

Revision History 

  • Version 1.0: 2014-02-12
    Type: Initial release